Drug Profile
BAL 3833
Alternative Names: BAL3833; CCT 3833Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator The Institute of Cancer Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors; Ras signal transduction pathway inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in United Kingdom (PO, Capsule)
- 01 Jun 2020 Basilea plans to discontinue the development of BAL 3833 for Solid tumours
- 31 Dec 2018 Institute of Cancer Research completes a phase I trial in Solid tumours (Late-stage disease) in United Kingdom (PO) (NCT02437227)